Jubilant Ingrevia Q2FY27 EBITDA rises 57% year over year
Anand Rathi reports EBITDA up 57% year over year and 7% quarter over quarter, and 12% ahead of estimates. The report cites ramp-up in Human/Cosmetic grade B3 and improved pricing in Niacinamide and Acetyls.